Vera Therapeutics, Inc.
VERA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831828
In the last 90 days, Vera Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 219 institutions reported holding it in 13F filings for Q2 2026, worth $3.34B in total; no superinvestor holds it.
Holders of 5% or more of VERA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Vera Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 13G/A | 8.90%5.61M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 7.40%5.34M shares | – | Jul 30, 20261 filing | Jul 30, 2026 | SEC |
| Price T Rowe Associates Inc | 13G/A | 6.40%4.57M shares | −1.30 ppfrom 7.70% | Nov 14, 20253 filings | May 15, 2026 | SEC |
| State Street Corp | 13G | 5.80%4.15M shares | New | Aug 7, 20261 filing | Aug 7, 2026 | SEC |
| Deep Track Capital, LP | 13G | 5.50%3.92M shares | New | Mar 11, 20261 filing | Mar 11, 2026 | SEC |
| Flynn James E | 13G | 5.25%3.35M shares | New | Jun 11, 20251 filing | Jun 11, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
15 Schedule 13D and 13G filings on Vera Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 20261:50 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −5.03 ppfrom 5.03%Below 5% | Mar 13, 2026 | SEC |
| Mar 11, 20264:05 PM ET | Deep Track Capital, LPand 2 others | 13G | 5.50%3.92M shares | New | Mar 4, 2026 | SEC |
| Mar 5, 20266:11 AM ET | Sofinnova Venture Partners X, L.P.and 4 others | 13D/A | 4.00%2.85M shares | –Below 5% | Dec 10, 2025 | SEC |
| Feb 17, 202610:26 AM ET | Price T Rowe Associates Inc | 13G/A | 7.70%5.46M shares | +2.00 ppfrom 5.70% | Dec 31, 2025 | SEC |
| Feb 5, 20261:40 PM ET | FMR LLCand 1 other | 13G/A | 4.10%2.89M shares | –Below 5% | Dec 31, 2025 | SEC |
| Jan 30, 20262:43 PM ET | Vanguard Group Inc | 13G | 5.03%3.57M shares | New | Dec 31, 2025 | SEC |
| Nov 14, 202512:19 PM ET | Price T Rowe Associates Inc | 13G/A | 5.70%3.67M shares | – | Sep 30, 2025 | SEC |
| Aug 14, 202511:00 AM ET | Kynam Capital Management, LPand 2 others | 13G | 5.37%3.43M shares | New | Jun 30, 2025 | SEC |
| Jun 11, 20255:38 PM ET | Flynn James Eand 3 others | 13G | 5.25%3.35M shares | New | Jun 6, 2025 | SEC |
| Feb 14, 20259:30 AM ET | Avoro Capital Advisors LLCand 1 other | 13G/A | 8.90%5.61M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Vera Therapeutics, Inc. shares.
No Form 144 notices for Vera Therapeutics, Inc. are on file.